Results 121 to 130 of about 115,105 (360)

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

Arthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Drugs for discoid lupus erythematosus [PDF]

, 2017
BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is
Grainge, Matthew J., Jayasekera, Prativa, Jessop, Sue, Whitelaw, David A.   +3 more
core   +2 more sources

The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity [PDF]

, 2020
Αrgyris Τzouvelekis, Τheodoros Karampitsakos, Demosthenes Bouros   +2 more
openalex   +1 more source

Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE [PDF]

, 2019
Objective Patients with SLE have an increased risk ofatherosclerosis (ATH) that is not adequately explainedby traditional risk factors. We previously described thePredictors of Risk for Elevated Flares, Damage Progression,and Increased Cardiovascular ...
Chen, Weiling, Grossman, Jennifer, Hahn, Bevra, McMahon, Maureen, Sahakian, Lori, Skaggs, Brian, Wong, Weng Kee   +6 more
core  

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source

For the eye altering, alters the all [PDF]

, 2015
C
Boey, Olivier, Bogaert, Anne-Marie, De Scheerder, Marie-Angélique, Mahieu, Elien, Vanuytsel, Johan   +4 more
core   +1 more source

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. [PDF]

, 2020
The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2.
Ansari, Aftab A, Ceribelli, Angela, De Santis, Maria, Gershwin, M Eric, Motta, Francesca, Ridgway, William M, Selmi, Carlo   +6 more
core  

Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro [PDF]

, 2018
We recently showed that patients with primary Sjögren Syndrome (pSS) have significantly higher bone mineral density (BMD) compared to healthy controls.
Both, T. (Tim), Daele, P.L.A. (Paul) van, Eerden, B.C.J. (Bram) van der, Hagen, P.M. (Martin) van, Koedam, M. (Marijke), Leeuwen, J.P.T.M. (Hans) van, van de Peppel, H.J. (H. Jeroen), Zillikens, M.C. (Carola)   +7 more
core   +1 more source

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Annals of the Rheumatic Diseases, 2020
The current outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) represents a source of concern for the management of patients with systemic lupus erythematosus (SLE). Indeed patients with SLE have an increased
A. Mathian, M. Mahévas, J. Rohmer, M. Roumier, F. Cohen-Aubart, Blanca Amador-Borrero, A. Barrelet, C. Chauvet, T. Chazal, M. Delahousse, M. Devaux, R. Euvrard, Jehane Fadlallah, Nans Florens, J. Haroche, M. Hié, L. Juillard, R. Lhote, T. Maillet, Gaelle Richard-Colmant, Jean Baptiste Palluy, M. Pha, L. Pérard, P. Rémy, E. Rivière, D. Sène, P. Sève, C. Morélot-Panzini, J. Viallard, J. Virot, Neila Benameur, N. Zahr, H. Yssel, B. Godeau, Z. Amoura   +34 more
semanticscholar   +1 more source

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti, Giacomo Emmi, Alessandra Bettiol, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Francesca Nencini, Maria Nicastro, Irene Mattioli, Elena Silvestri, Augusto Vaglio, Domenico Prisco, Claudia Fiorillo   +13 more
wiley   +1 more source